BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38215513)

  • 1. Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
    Gressel GM; Frey MK; Norquist B; Senter L; Blank SV; Urban RR
    Gynecol Oncol; 2024 Feb; 181():170-178. PubMed ID: 38215513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
    Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
    Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline Testing and Somatic Tumor Testing for
    Kwon JS; Tinker AV; Santos J; Compton K; Sun S; Schrader KA; Karsan A
    JCO Precis Oncol; 2022 Oct; 6():e2200033. PubMed ID: 36265114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R
    Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic testing in ovarian cancer - clinical impact and current practices.
    Knabben L; Imboden S; Mueller MD
    Horm Mol Biol Clin Investig; 2019 Oct; 41(3):. PubMed ID: 31577534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
    Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of germline pathogenic
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted molecular profiling of epithelial ovarian cancer from Italian BRCA wild-type patients with a BRCA and PARP pathways gene panel.
    Salvati A; Carnevali I; Alexandrova E; Facchi S; Ronchi S; Libera L; Sahnane N; Memoli D; Lamberti J; Amabile S; Pepe S; Tarallo R; Sessa F; Weisz A; Tibiletti MG; Rizzo F
    Exp Mol Pathol; 2022 Oct; 128():104833. PubMed ID: 36165864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
    Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
    Kim HK; Lee EJ; Lee YJ; Kim J; Kim Y; Kim K; Lee SW; Chang S; Lee YJ; Lee JW; Lee W; Chun S; Son BH; Jung KH; Kim YM; Min WK; Ahn SH
    J Hum Genet; 2020 Mar; 65(3):209-220. PubMed ID: 31907386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
    Capoluongo E; Ellison G; López-Guerrero JA; Penault-Llorca F; Ligtenberg MJL; Banerjee S; Singer C; Friedman E; Markiefka B; Schirmacher P; Büttner R; van Asperen CJ; Ray-Coquard I; Endris V; Kamel-Reid S; Percival N; Bryce J; Röthlisberger B; Soong R; de Castro DG
    Semin Oncol; 2017 Jun; 44(3):187-197. PubMed ID: 29248130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
    Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
    Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    Moschetta M; George A; Kaye SB; Banerjee S
    Ann Oncol; 2016 Aug; 27(8):1449-55. PubMed ID: 27037296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.